Rebecca Kinsley

Madingley Road
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.

Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.

Journal: The Journal of general virology
Published: October 06, 2025

A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.

A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.

Journal: The Journal of infection
Published: September 09, 2025

Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD.

Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD.

Journal: Emerging microbes & infections
Published: May 06, 2025

Immunological insights into COVID-19 in Southern Nigeria.

Immunological insights into COVID-19 in Southern Nigeria.

Journal: Frontiers in immunology
Published: October 02, 2023

Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.

Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.

Journal: NPJ vaccines
Published: July 29, 2023

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.

Journal: Frontiers in immunology
Published: December 07, 2022

Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria.

Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria.

Journal: Scientific reports
Published: October 17, 2022

Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design.

Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design.

Journal: Vaccines
Published: August 10, 2022

A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses.

A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses.

Journal: Nature biomedical engineering
Published: November 05, 2021

Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection.

Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection.

Journal: Vaccines
Published: May 09, 2021

Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.

Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.

Journal: Frontiers in immunology
Published: January 30, 2021

Evaluation of a Pseudotyped Virus Neutralisation Test for the Measurement of Equine Influenza Virus-Neutralising Antibody Responses Induced by Vaccination and Infection.

Evaluation of a Pseudotyped Virus Neutralisation Test for the Measurement of Equine Influenza Virus-Neutralising Antibody Responses Induced by Vaccination and Infection.

Journal: Vaccines
Published: July 11, 2020
Showing 1-12 of 14

Last Updated: 09/26/2026